Since its discovery in 1998, AKR1B10 has been investigated as a potential biomarker in a number of oncological diseases, including breast, lung, endometrial, bladder, and renal cell carcinomas, as well as in a number of chronic diseases, such as alcoholic hepatitis, NAFLD, and benign prostatic hyperplasia (40, 104–110). Here, AKR1B10 is linked to benign prostatic hyperplasia.